Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mecxin-BT is a fixed-dose combination pharmaceutical product developed by Stevia Pharmaceuticals, primarily indicated for the management of diabetic neuropathy and peripheral neuropathy. The formulation consists of five active ingredients: mecobalamin (a neuroactive form of Vitamin B12), benfotiamine (a lipid-soluble thiamine derivative), thioctic acid (alpha-lipoic acid), pyridoxine (Vitamin B6), and folic acid. Mecobalamin facilitates the synthesis of the myelin sheath and promotes axonal regeneration. Benfotiamine helps prevent the formation of advanced glycation end products (AGEs) by activating the enzyme transketolase. Thioctic acid serves as a potent antioxidant that improves endoneurial blood flow and nerve conduction. Pyridoxine and folic acid act as essential cofactors in nerve metabolism and homocysteine regulation. Together, these components work synergistically to alleviate symptoms such as pain, numbness, and tingling associated with chronic nerve damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benfotiamine + folic acid + mecobalamin + pyridoxine + thioctic acid.